FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387563325> ?p ?o ?g. }

• W4387563325 abstract "Australasian Journal of DermatologyEarly View LETTER Burden of proof—Critical flaws in the recommendations from the commission on human medicines Isotretinoin expert working group Eugene Tan MBChB, FACD, Corresponding Author Eugene Tan MBChB, FACD [email protected] orcid.org/0000-0001-7935-9179 Department of Dermatology, Skintel, Auckland, New Zealand Correspondence Eugene Tan, Department of Dermatology, Skintel, 11 Apollo Drive, Rosedale, Auckland 0632, New Zealand. Email: [email protected]Search for more papers by this authorHarriet Kennedy MBChB, FNZDS, Harriet Kennedy MBChB, FNZDS Auckland City Hospital, Te Whatu Ora, New Zealand Faculty of Medical and Health Sciences, University of Auckland, Auckland, New ZealandSearch for more papers by this authorMarius Rademaker DM, FACD, Marius Rademaker DM, FACD orcid.org/0000-0003-3393-6748 Clinical Trials New Zealand, Waikato Hospital Campus, Hamilton, New ZealandSearch for more papers by this author Eugene Tan MBChB, FACD, Corresponding Author Eugene Tan MBChB, FACD [email protected] orcid.org/0000-0001-7935-9179 Department of Dermatology, Skintel, Auckland, New Zealand Correspondence Eugene Tan, Department of Dermatology, Skintel, 11 Apollo Drive, Rosedale, Auckland 0632, New Zealand. Email: [email protected]Search for more papers by this authorHarriet Kennedy MBChB, FNZDS, Harriet Kennedy MBChB, FNZDS Auckland City Hospital, Te Whatu Ora, New Zealand Faculty of Medical and Health Sciences, University of Auckland, Auckland, New ZealandSearch for more papers by this authorMarius Rademaker DM, FACD, Marius Rademaker DM, FACD orcid.org/0000-0003-3393-6748 Clinical Trials New Zealand, Waikato Hospital Campus, Hamilton, New ZealandSearch for more papers by this author First published: 11 October 2023 https://doi.org/10.1111/ajd.14169Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Australasian College of Dermatologists. The ACD position statement on isotretinoin for treatment of acne – updated Aug 2023. 2023. Available from: https://www.dermcoll.edu.au/wp-content/uploads/2023/08/ACD-Position-Statement-Isotretinoin-August-2023-Final-version.pdf. Accessed Aug 2023. 2 Commission on Human Medicines. Report of the Commission on Human Medicines Isotretinoin Expert Working Group. 2023. Available from: https://www.gov.uk/government/publications/report-of-the-commission-on-human-medicines-isotretinoin-expert-working-group. Accessed Jul 2023. 3Allen RJ. Burdens of proof. Law Probab Risk. 2014; 13: 195–219. 4Sagan C. The demon-haunted world: science as a candle in the dark. New York, NY: Random House; 1996. p. 160–162. 5Namita K, Ida-Lina D, Allen B, Shewit B, Mark A, Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011; 65: 546–551. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation" @default.
• W4387563325 created "2023-10-13" @default.
• W4387563325 creator A5006757385 @default.
• W4387563325 creator A5034351514 @default.
• W4387563325 creator A5070781484 @default.
• W4387563325 date "2023-10-11" @default.
• W4387563325 modified "2023-10-13" @default.
• W4387563325 title "Burden of proof—Critical flaws in the recommendations from the commission on human medicines Isotretinoin expert working group" @default.
• W4387563325 cites W2071972324 @default.
• W4387563325 cites W3125909191 @default.
• W4387563325 doi "https://doi.org/10.1111/ajd.14169" @default.
• W4387563325 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37822144" @default.
• W4387563325 hasPublicationYear "2023" @default.
• W4387563325 type Work @default.
• W4387563325 citedByCount "0" @default.
• W4387563325 crossrefType "journal-article" @default.
• W4387563325 hasAuthorship W4387563325A5006757385 @default.
• W4387563325 hasAuthorship W4387563325A5034351514 @default.
• W4387563325 hasAuthorship W4387563325A5070781484 @default.
• W4387563325 hasConcept C161191863 @default.
• W4387563325 hasConcept C41008148 @default.
• W4387563325 hasConcept C512399662 @default.
• W4387563325 hasConcept C71924100 @default.
• W4387563325 hasConceptScore W4387563325C161191863 @default.
• W4387563325 hasConceptScore W4387563325C41008148 @default.
• W4387563325 hasConceptScore W4387563325C512399662 @default.
• W4387563325 hasConceptScore W4387563325C71924100 @default.
• W4387563325 hasLocation W43875633251 @default.
• W4387563325 hasLocation W43875633252 @default.
• W4387563325 hasOpenAccess W4387563325 @default.
• W4387563325 hasPrimaryLocation W43875633251 @default.
• W4387563325 hasRelatedWork W1506200166 @default.
• W4387563325 hasRelatedWork W1995515455 @default.
• W4387563325 hasRelatedWork W2048182022 @default.
• W4387563325 hasRelatedWork W2080531066 @default.
• W4387563325 hasRelatedWork W2604872355 @default.
• W4387563325 hasRelatedWork W2748952813 @default.
• W4387563325 hasRelatedWork W2899084033 @default.
• W4387563325 hasRelatedWork W3031052312 @default.
• W4387563325 hasRelatedWork W3032375762 @default.
• W4387563325 hasRelatedWork W3108674512 @default.
• W4387563325 isParatext "false" @default.
• W4387563325 isRetracted "false" @default.
• W4387563325 workType "article" @default.